AU2002356720B2 - Hexacyclic compounds - Google Patents

Hexacyclic compounds Download PDF

Info

Publication number
AU2002356720B2
AU2002356720B2 AU2002356720A AU2002356720A AU2002356720B2 AU 2002356720 B2 AU2002356720 B2 AU 2002356720B2 AU 2002356720 A AU2002356720 A AU 2002356720A AU 2002356720 A AU2002356720 A AU 2002356720A AU 2002356720 B2 AU2002356720 B2 AU 2002356720B2
Authority
AU
Australia
Prior art keywords
ethyl
hydroxy
pyrido
indolizino
quinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002356720A
Other languages
English (en)
Other versions
AU2002356720A1 (en
Inventor
Takeshi Murata
Satoshi Niizuma
Nobuo Shimma
Hitomi Suda
Masao Tsukazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2002356720A1 publication Critical patent/AU2002356720A1/en
Application granted granted Critical
Publication of AU2002356720B2 publication Critical patent/AU2002356720B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2002356720A 2001-11-30 2002-11-25 Hexacyclic compounds Ceased AU2002356720B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01128361.1 2001-11-30
EP01128361 2001-11-30
PCT/EP2002/013216 WO2003045952A2 (en) 2001-11-30 2002-11-25 Condensed camptothecins as antitumor agents

Publications (2)

Publication Number Publication Date
AU2002356720A1 AU2002356720A1 (en) 2003-06-10
AU2002356720B2 true AU2002356720B2 (en) 2009-01-29

Family

ID=8179394

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002356720A Ceased AU2002356720B2 (en) 2001-11-30 2002-11-25 Hexacyclic compounds

Country Status (28)

Country Link
US (2) US6825194B2 (enExample)
EP (1) EP1480984B9 (enExample)
JP (1) JP4305909B2 (enExample)
KR (1) KR100895746B1 (enExample)
CN (1) CN100338066C (enExample)
AT (1) ATE398131T1 (enExample)
AU (1) AU2002356720B2 (enExample)
BR (1) BR0214615A (enExample)
CA (1) CA2468824C (enExample)
DE (1) DE60227113D1 (enExample)
ES (1) ES2307830T3 (enExample)
GT (1) GT200200250A (enExample)
HU (1) HUP0500062A3 (enExample)
IL (1) IL162058A0 (enExample)
MX (1) MXPA04005185A (enExample)
MY (1) MY136138A (enExample)
NO (1) NO329005B1 (enExample)
NZ (1) NZ533568A (enExample)
PA (1) PA8558901A1 (enExample)
PE (1) PE20030725A1 (enExample)
PL (1) PL207510B1 (enExample)
RS (1) RS51051B (enExample)
RU (1) RU2299212C2 (enExample)
TW (1) TWI258481B (enExample)
UA (1) UA80409C2 (enExample)
UY (1) UY27560A1 (enExample)
WO (1) WO2003045952A2 (enExample)
ZA (1) ZA200404522B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073601A2 (en) * 2003-02-21 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Process for the preparation of hexacyclic camptothecin derivatives
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US20090118271A1 (en) * 2005-10-19 2009-05-07 Chugai Seiyaku Kabushiki Kaisha Preventive or Therapeutic Agents for Pancreatic Cancer, Ovarian Cancer, or Liver Cancer Comprising a Novel Water-Soluble Prodrug
RU2439073C1 (ru) * 2010-07-13 2012-01-10 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУ ВПО "КубГТУ") СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ ИНДОЛИЗИНО[7,6-b]ИНДОЛА
KR20240104214A (ko) 2019-03-29 2024-07-04 메디뮨 리미티드 화합물 및 이의 접합체

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296597A2 (en) * 1987-06-24 1988-12-28 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
HU213136B (en) * 1990-08-14 1997-02-28 Kyorin Seiyaku Kk Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them
JP3008226B2 (ja) * 1991-01-16 2000-02-14 第一製薬株式会社 六環性化合物
JP3359955B2 (ja) * 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5663177A (en) * 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
DE69834923T2 (de) 1997-02-14 2006-10-19 Bionumerik Pharmaceuticals, Inc., San Antonio Hochgradig lipophile camptothecin-derivate
GB9715821D0 (en) * 1997-07-25 1997-10-01 Pharmacia & Upjohn Spa Amidino-camptothecin derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296597A2 (en) * 1987-06-24 1988-12-28 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound

Also Published As

Publication number Publication date
KR100895746B1 (ko) 2009-04-30
MXPA04005185A (es) 2004-08-11
PL370479A1 (en) 2005-05-30
AU2002356720A1 (en) 2003-06-10
RU2004119841A (ru) 2005-03-27
ATE398131T1 (de) 2008-07-15
HUP0500062A3 (en) 2012-12-28
IL162058A0 (en) 2005-11-20
PA8558901A1 (es) 2003-06-30
NO20042729L (no) 2004-08-27
US6825194B2 (en) 2004-11-30
EP1480984B9 (en) 2009-03-11
RU2299212C2 (ru) 2007-05-20
JP2005511643A (ja) 2005-04-28
HK1077303A1 (en) 2006-02-10
TWI258481B (en) 2006-07-21
UY27560A1 (es) 2003-05-30
US20030144304A1 (en) 2003-07-31
ZA200404522B (en) 2005-01-04
MY136138A (en) 2008-08-29
CN100338066C (zh) 2007-09-19
PE20030725A1 (es) 2003-08-28
NO329005B1 (no) 2010-07-19
UA80409C2 (en) 2007-09-25
WO2003045952A3 (en) 2003-10-16
GT200200250A (es) 2004-01-15
PL207510B1 (pl) 2010-12-31
US20050059679A1 (en) 2005-03-17
ES2307830T3 (es) 2008-12-01
RS47004A (sr) 2007-02-05
TW200408642A (en) 2004-06-01
DE60227113D1 (de) 2008-07-24
CA2468824C (en) 2011-01-11
JP4305909B2 (ja) 2009-07-29
WO2003045952A2 (en) 2003-06-05
RS51051B (sr) 2010-10-31
KR20040062976A (ko) 2004-07-09
US7109195B2 (en) 2006-09-19
HUP0500062A2 (hu) 2005-04-28
EP1480984B1 (en) 2008-06-11
BR0214615A (pt) 2004-09-14
CN1617874A (zh) 2005-05-18
CA2468824A1 (en) 2003-06-05
HK1072935A1 (en) 2005-09-16
NZ533568A (en) 2006-01-27
EP1480984A2 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
JP7280928B2 (ja) 脱ユビキチン化酵素（ｄｕｂ）阻害剤としてのスピロ縮合ピロリジン誘導体
AU2020394767B2 (en) Spiro compound serving as ERK inhibitor, and application thereof
DE69332504T2 (de) Trifluoromethylpyrroloindolcarbonsäure und dessen esterderivat sowie ein verfahren zu seiner herstellung
CN116096372A (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
CN108069946B (zh) 具有穿过血脑屏障能力的取代的喹唑啉化合物
NO341812B1 (no) Camptotecinderivater med antitumoraktivitet
AU2019375825B2 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
US20230295163A1 (en) Tetracyclic derivative, method for preparing same and use thereof in medicine
US20090312554A1 (en) Novel Process for the Preparation of Hexacyclic Compounds
CN117624179A (zh) 3-(氨基)亚甲基吲哚啉类衍生物及其制备方法和应用
JP4923067B2 (ja) カンプトテシン誘導体及びその応用
US6825194B2 (en) Hexacyclic compounds
CN115433207A (zh) 作为egfr抑制剂的大环杂环类化合物及其应用
CN120383584A (zh) 喹唑啉酮衍生物及其制备方法和用途
AU2006305169A1 (en) Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug
HK1072935B (en) Hexacyclic compounds
HK1072935C (en) Hexacyclic compounds

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HEXACYCLIC COMPOUNDS.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HEXACYCLIC COMPOUNDS

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired